LAVA Therapeutics NV (LVTX)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| Foreign currency translation adjustment | 2,349 | 978 | ||
| Income tax expense, net | 72 | 225 | ||
| Research and development | 4,739 | 4,156 | ||
| General and administrative | 2,550 | 3,432 | ||
| Total cost and expenses | 7,289 | 7,588 | ||
| Operating loss | -7,289 | -7,588 | ||
| Interest expense | - | 129 | ||
| Gain on extinguishment of borrowings | - | 5,203 | ||
| Interest income | 607 | 713 | ||
| Foreign currency exchange (loss) gain, net | -1,885 | -1,453 | ||
| Total other income (expense), net | -1,278 | 4,334 | ||
| Net loss before taxes | -8,567 | -3,254 | ||
| Net loss | -8,639 | -3,479 | ||
| Comprehensive loss | -6,290 | -2,501 | ||
| Earnings per share, basic | -0.32 | -0.13 | ||
| Earnings per share, diluted | -0.32 | -0.13 | ||
| Weighted average number of shares outstanding, basic | 26,899,122 | 26,892,575 | ||
| Weighted average number of shares outstanding, diluted | 26,899,122 | 26,892,575 | ||